Moderating effect of ppar-γ on the association of c-reactive protein and ischemic stroke in patients younger than 60

Martinović, Ana; Merkler, Ana; Celić, Igor; Starčević, Katarina; Simić, Miloš; Karmelić, Ivana; Poljaković, Zdravka; Kalinić, Dubravka; Sertić, Jadranka

doi:10.1016/j.gene.2021.146029

Cited by 2 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 15 ] However, the severe complications associated with the long‐term use of these agents and weight gain led to the recall of troglitazone [ 16 ] and rosiglitazone [ 17 ] from the market. In recent years, the involvement of PPAR‐γ in other disorders such as cardiovascular disorders, [ 18,19 ] Alzheimer's, [ 20 ] and Parkinson's disease, [ 21 ] multiple sclerosis, [ 22 ] stroke, [ 23,24 ] and cancer [ 25,26 ] have been extensively exploited. These findings prompted the repurposing of troglitazone and rosiglitazone as potential anticancer agents, [ 27,28 ] which are still under clinical development.…”

Section: Introductionmentioning

confidence: 99%

The medicinal perspective of 2,4‐thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review

Singh

Kajal

Pradhan

et al. 2022

Archiv der Pharmazie

View full text Add to dashboard Cite

2,4-Thiazolidinedione (2,4-TZD), commonly known as glitazone, is a ubiquitous heterocyclic pharmacophore possessing a plethora of pharmacological activities and offering a vast opportunity for structural modification. The diverse range of biological activities endowed with a novel mode of action, low cost, and easy synthesis has attracted the attention of medicinal chemists. Several researchers have integrated the TZD core with different structural fragments to develop a wide range of lead molecules against various clinical disorders. The most common sites for structural modifications at the 2,4-TZD nucleus are the N-3 and the active methylene at C-5. The review covers the recent development of TZD derivatives such as antimicrobial, anticancer, and antidiabetic agents. Various 2,4-TZD based agents or drugs, which are either under clinical development or in the market, are discussed in the study. Different synthetic methodologies for synthesizing the 2,4-TZD core are also included in the manuscript.The importance of various substitutions at N-3 and C-5 and the mechanisms of action and structure-activity relationships are also discussed. We hope this study will serve as a valuable tool for the scientific community engaged in the structural exploitation of the 2,4-TZD core for developing novel drug m\olecules for life-threatening ailments.

show abstract

Section: Introductionmentioning

confidence: 99%

The medicinal perspective of 2,4‐thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review

Singh

Kajal

Pradhan

et al. 2022

Archiv der Pharmazie

View full text Add to dashboard Cite

show abstract

“…PPARs have multiple and complex physiological functions, involving lipid and glucose metabolism, ( 8 , 9 ) inflammatory response, ( 10 , 11 ) oxidative stress, ( 11 , 12 ) cell differentiation and apoptosis, ( 13 , 14 ) and even cognitive function ( 15 ). PPARs have been implicated in the pathogenesis of a number of major human diseases, such as cardiovascular and cerebrovascular diseases, ( 16 , 17 ) malignant tumors, ( 18 , 19 ) diabetes mellitus, ( 20 , 21 ) metabolic syndrome, ( 22 ) and neurodegenerative disorders ( 23 ). PPARs have three subtypes: PPARα, PPARβ/δ, and PPARγ.…”

Section: Introductionmentioning

confidence: 99%

PPARγ Gene Polymorphisms, Metabolic Disorders, and Coronary Artery Disease

Song

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Being activated by endogenous and exogenous ligands, nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) enhances insulin sensitivity, promotes adipocyte differentiation, stimulates adipogenesis, and has the properties of anti-atherosclerosis, anti-inflammation, and anti-oxidation. The Human PPARγ gene (PPARG) contains thousands of polymorphic loci, among them two polymorphisms (rs10865710 and rs7649970) in the promoter region and two polymorphisms (rs1801282 and rs3856806) in the exonic region were widely reported to be significantly associated with coronary artery disease (CAD). Mechanistically, PPARG polymorphisms lead to abnormal expression of PPARG gene and/or dysfunction of PPARγ protein, causing metabolic disorders such as hypercholesterolemia and hypertriglyceridemia, and thereby increasing susceptibility to CAD.

show abstract

Moderating effect of ppar-γ on the association of c-reactive protein and ischemic stroke in patients younger than 60

Cited by 2 publications

References 38 publications

The medicinal perspective of 2,4‐thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review

The medicinal perspective of 2,4‐thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review

PPARγ Gene Polymorphisms, Metabolic Disorders, and Coronary Artery Disease

Contact Info

Product

Resources

About